Polycythemia vera treatment algorithm 2018

Ayalew Tefferi, Alessandro M. Vannucchi, Tiziano Barbui

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Recently reported mature survival data have confirmed the favorable prognosis in polycythemia vera (PV), with an estimated median survival of 24 years, in patients younger than age 60 years old. Currently available drugs for PV have not been shown to prolong survival or alter the natural history of the disease and are instead indicated primarily for prevention of thrombosis. Unfortunately, study endpoints that are being utilized in currently ongoing clinical trials in PV do not necessarily target clinically or biologically relevant outcomes, such as thrombosis, survival, or morphologic remission, and are instead focused on components of disease palliation. Even more discouraging has been the lack of critical appraisal from "opinion leaders", on the added value of newly approved drugs. Keeping these issues in mind, at present, we continue to advocate conservative management in low-risk PV (phlebotomy combined with once- or twice-daily aspirin therapy) and include cytoreductive therapy in "high-risk" patients; in the latter regard, our first, second, and third line drugs of choice are hydroxyurea, pegylated interferon-α and busulfan, respectively. In addition, it is reasonable to consider JAK2 inhibitor therapy, in the presence of protracted pruritus or markedly enlarged splenomegaly shown to be refractory to the aforementioned drugs.

Original languageEnglish (US)
Article number3
JournalBlood Cancer Journal
Volume8
Issue number1
DOIs
StatePublished - Jan 1 2018

Fingerprint

Polycythemia Vera
Survival
Pharmaceutical Preparations
Thrombosis
Busulfan
Phlebotomy
Hydroxyurea
Splenomegaly
Therapeutics
Pruritus
Interferons
Aspirin
Clinical Trials

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Polycythemia vera treatment algorithm 2018. / Tefferi, Ayalew; Vannucchi, Alessandro M.; Barbui, Tiziano.

In: Blood Cancer Journal, Vol. 8, No. 1, 3, 01.01.2018.

Research output: Contribution to journalArticle

Tefferi, Ayalew ; Vannucchi, Alessandro M. ; Barbui, Tiziano. / Polycythemia vera treatment algorithm 2018. In: Blood Cancer Journal. 2018 ; Vol. 8, No. 1.
@article{42201402f8574ae69fe5e39107b8b6f9,
title = "Polycythemia vera treatment algorithm 2018",
abstract = "Recently reported mature survival data have confirmed the favorable prognosis in polycythemia vera (PV), with an estimated median survival of 24 years, in patients younger than age 60 years old. Currently available drugs for PV have not been shown to prolong survival or alter the natural history of the disease and are instead indicated primarily for prevention of thrombosis. Unfortunately, study endpoints that are being utilized in currently ongoing clinical trials in PV do not necessarily target clinically or biologically relevant outcomes, such as thrombosis, survival, or morphologic remission, and are instead focused on components of disease palliation. Even more discouraging has been the lack of critical appraisal from {"}opinion leaders{"}, on the added value of newly approved drugs. Keeping these issues in mind, at present, we continue to advocate conservative management in low-risk PV (phlebotomy combined with once- or twice-daily aspirin therapy) and include cytoreductive therapy in {"}high-risk{"} patients; in the latter regard, our first, second, and third line drugs of choice are hydroxyurea, pegylated interferon-α and busulfan, respectively. In addition, it is reasonable to consider JAK2 inhibitor therapy, in the presence of protracted pruritus or markedly enlarged splenomegaly shown to be refractory to the aforementioned drugs.",
author = "Ayalew Tefferi and Vannucchi, {Alessandro M.} and Tiziano Barbui",
year = "2018",
month = "1",
day = "1",
doi = "10.1038/s41408-017-0042-7",
language = "English (US)",
volume = "8",
journal = "Blood Cancer Journal",
issn = "2044-5385",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Polycythemia vera treatment algorithm 2018

AU - Tefferi, Ayalew

AU - Vannucchi, Alessandro M.

AU - Barbui, Tiziano

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Recently reported mature survival data have confirmed the favorable prognosis in polycythemia vera (PV), with an estimated median survival of 24 years, in patients younger than age 60 years old. Currently available drugs for PV have not been shown to prolong survival or alter the natural history of the disease and are instead indicated primarily for prevention of thrombosis. Unfortunately, study endpoints that are being utilized in currently ongoing clinical trials in PV do not necessarily target clinically or biologically relevant outcomes, such as thrombosis, survival, or morphologic remission, and are instead focused on components of disease palliation. Even more discouraging has been the lack of critical appraisal from "opinion leaders", on the added value of newly approved drugs. Keeping these issues in mind, at present, we continue to advocate conservative management in low-risk PV (phlebotomy combined with once- or twice-daily aspirin therapy) and include cytoreductive therapy in "high-risk" patients; in the latter regard, our first, second, and third line drugs of choice are hydroxyurea, pegylated interferon-α and busulfan, respectively. In addition, it is reasonable to consider JAK2 inhibitor therapy, in the presence of protracted pruritus or markedly enlarged splenomegaly shown to be refractory to the aforementioned drugs.

AB - Recently reported mature survival data have confirmed the favorable prognosis in polycythemia vera (PV), with an estimated median survival of 24 years, in patients younger than age 60 years old. Currently available drugs for PV have not been shown to prolong survival or alter the natural history of the disease and are instead indicated primarily for prevention of thrombosis. Unfortunately, study endpoints that are being utilized in currently ongoing clinical trials in PV do not necessarily target clinically or biologically relevant outcomes, such as thrombosis, survival, or morphologic remission, and are instead focused on components of disease palliation. Even more discouraging has been the lack of critical appraisal from "opinion leaders", on the added value of newly approved drugs. Keeping these issues in mind, at present, we continue to advocate conservative management in low-risk PV (phlebotomy combined with once- or twice-daily aspirin therapy) and include cytoreductive therapy in "high-risk" patients; in the latter regard, our first, second, and third line drugs of choice are hydroxyurea, pegylated interferon-α and busulfan, respectively. In addition, it is reasonable to consider JAK2 inhibitor therapy, in the presence of protracted pruritus or markedly enlarged splenomegaly shown to be refractory to the aforementioned drugs.

UR - http://www.scopus.com/inward/record.url?scp=85040454490&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040454490&partnerID=8YFLogxK

U2 - 10.1038/s41408-017-0042-7

DO - 10.1038/s41408-017-0042-7

M3 - Article

C2 - 29321547

AN - SCOPUS:85040454490

VL - 8

JO - Blood Cancer Journal

JF - Blood Cancer Journal

SN - 2044-5385

IS - 1

M1 - 3

ER -